Related Experiment Videos
Prognosis in children with metastatic rhabdomyosarcoma
Insights
Rhabdomyosarcoma metastasis in children is rare, with most deaths occurring within 24 months. Survival rates for pediatric rhabdomyosarcoma with distant metastases remain very low, highlighting the need for improved treatments.
Area of Science:
- Pediatric Oncology
- Cancer Metastasis Research
- Rhabdomyosarcoma Studies
Background:
- Rhabdomyosarcoma is a rare childhood cancer.
- Distant metastases significantly impact prognosis in pediatric rhabdomyosarcoma.
- Historical data on metastatic rhabdomyosarcoma outcomes is crucial for understanding disease progression.
Purpose of the Study:
- To analyze the incidence and outcomes of distant metastases in pediatric rhabdomyosarcoma.
- To evaluate survival rates and time to metastasis in different patient groups.
- To provide insights into the natural history of metastatic rhabdomyosarcoma.
Main Methods:
- Retrospective review of 161 children diagnosed with rhabdomyosarcoma between 1953 and 1974.
- Categorization of patients based on metastasis status at diagnosis and autopsy.
- Analysis of survival duration and time to metastasis.
Main Results:
- 83 of 161 children had documented distant metastases.
- Only 6 patients survived with no evidence of disease, with survival times ranging from 6 to 112 months.
- The majority of deaths (64/66) occurred within 24 months of metastasis.
- Median survival after metastasis was less than 9 months for most groups, with Group IV (metastasis at diagnosis) having a median survival of approximately 12 months.
Conclusions:
- Distant metastasis in pediatric rhabdomyosarcoma is associated with a poor prognosis.
- Survival rates for children with metastatic rhabdomyosarcoma are critically low.
- The findings underscore the urgent need for advancements in the treatment of metastatic rhabdomyosarcoma.
Abstract:
Distant metastases were documented in 83 of 161 children with rhabdomyosarcoma seen between 1953 and 1974. Of these, 31 had metastases at diagnosis (Group IV) and 7 were noted to have metastases only at autopsy. Only 6 are living with no evidence of disease activity at 6, 20, 77, 85, 105, and 112 months from time of metastasis. One child is living with disease at 98 months. Late deaths occurred in 2 at 31 and 41 months after metastasis. Sixty-four of the 66 deaths occurred within 24 months. The median durations of life after metastasis were less than 9 months in Groups I and II patients, less than 6 months in Group III patients, and about 12 months in 31 Group IV patients. The median time to metastasis in Groups I, II, and III patients was 9 months.